Samalin Investment Counsel LLC Takes $218,000 Position in HCA Healthcare, Inc. $HCA

Samalin Investment Counsel LLC purchased a new stake in HCA Healthcare, Inc. (NYSE:HCA) during the 1st quarter, HoldingsChannel.com reports. The fund purchased 631 shares of the company’s stock, valued at approximately $218,000.

A number of other large investors also recently modified their holdings of the stock. Price T Rowe Associates Inc. MD grew its holdings in HCA Healthcare by 83.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,399,372 shares of the company’s stock worth $829,104,000 after buying an additional 1,091,416 shares in the last quarter. Nuveen Asset Management LLC grew its stake in shares of HCA Healthcare by 4.5% in the 4th quarter. Nuveen Asset Management LLC now owns 1,865,771 shares of the company’s stock worth $560,011,000 after acquiring an additional 81,105 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of HCA Healthcare by 49.1% during the first quarter. Goldman Sachs Group Inc. now owns 1,781,459 shares of the company’s stock valued at $615,583,000 after purchasing an additional 587,036 shares in the last quarter. GAMMA Investing LLC increased its stake in HCA Healthcare by 40,527.3% in the 1st quarter. GAMMA Investing LLC now owns 1,703,907 shares of the company’s stock valued at $5,887,850,000 after buying an additional 1,699,713 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of HCA Healthcare by 12.6% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,675,460 shares of the company’s stock worth $502,889,000 after buying an additional 188,093 shares during the last quarter. Institutional investors own 62.73% of the company’s stock.

HCA Healthcare Stock Performance

NYSE:HCA opened at $405.18 on Thursday. HCA Healthcare, Inc. has a 52-week low of $289.98 and a 52-week high of $417.14. The business’s fifty day moving average is $375.76 and its 200 day moving average is $355.47. The company has a debt-to-equity ratio of 69.07, a quick ratio of 0.86 and a current ratio of 0.98. The firm has a market cap of $94.81 billion, a price-to-earnings ratio of 17.03, a PEG ratio of 1.26 and a beta of 1.39.

HCA Healthcare (NYSE:HCA) last announced its quarterly earnings results on Friday, July 25th. The company reported $6.84 earnings per share for the quarter, beating the consensus estimate of $6.20 by $0.64. HCA Healthcare had a negative return on equity of 7,363.11% and a net margin of 8.21%.The firm had revenue of $18.61 billion for the quarter, compared to analysts’ expectations of $18.49 billion. During the same period in the prior year, the business posted $5.50 earnings per share. The company’s revenue was up 6.4% on a year-over-year basis. HCA Healthcare has set its FY 2025 guidance at 25.500-27.000 EPS. Research analysts predict that HCA Healthcare, Inc. will post 24.98 EPS for the current year.

HCA Healthcare Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Tuesday, September 16th will be given a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Tuesday, September 16th. HCA Healthcare’s payout ratio is 12.11%.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Wolfe Research lowered HCA Healthcare from an “outperform” rating to a “peer perform” rating in a report on Monday, July 28th. Stephens raised shares of HCA Healthcare to a “strong-buy” rating in a report on Monday, June 2nd. Robert W. Baird lifted their price objective on shares of HCA Healthcare from $380.00 to $423.00 and gave the stock a “neutral” rating in a research report on Thursday, August 14th. Cantor Fitzgerald restated an “overweight” rating and set a $444.00 price target on shares of HCA Healthcare in a research note on Tuesday. Finally, Morgan Stanley reduced their price objective on HCA Healthcare from $410.00 to $400.00 and set an “equal weight” rating for the company in a report on Monday, July 28th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, HCA Healthcare currently has an average rating of “Moderate Buy” and an average price target of $401.83.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.